The long-term objective of this application is determination of the three dimensional structure of APP by analysis of the structures of its individual functional domains. The cysteine-rich N-terminal domain has been expressed at high levels and purified to homogeneity. Optimization of expression constructs will be required for production of material suitable for X-ray crystallography and NMR. In order to better understand the physiological behavior of APP -- both in normal tissue and in the context of Alzheimer's disease -- attempts are being made to identify APP binding proteins in the body. The concentration is on isolating potential proteases that interact with the APP Kunitz inhibitor (APP-KI) domain. Successful cloning of one such candidate protease utilizing a directed cloning approach has been accomplished. The present application proposes to continue this search until a comprehensive inventory of all human serine proteases capable of interacting with APP-KI has been completed. This will enable establishment of the role that these proteases play in human disease. Related work is concerned with investigating the interactions of the Alzheimer's amyloid beta peptide and its fibrils with fibrin(ogen)-binding proteins. This group of investigators recently discovered that the amyloid beta peptide is a potent stimulator of human tissue plasminogen activator. This property of the beta peptide may in part explain the association of deposits of beta peptide in the cerebral vasculature (cerebral amyloid angiopathy) with hemorrhagic strokes, especially those that occur in conjunction with thrombolytic therapy. These findings also provide a basis for understanding the hemorrhagic phenotype of the genetic disease, hereditary cerebral hemorrhage with amyloidosis-Dutch type (HCHWA-D). In the work proposed in this application, a plan for mapping the functional epitopes on the amyloid beta peptide that account for its fibrin(ogen) mimicry, and the development of monoclonal antibodies that block the interaction of beta peptide with fibrin(ogen)-binding molecules were described. In addition, the design of amyloid beta peptide analogues that form soluble """"""""minifibrils"""""""" amenable to structural analysis by high resolution methods was described. Finally, these investigators intend to explore whether synergistic interactions occur in the CNS between fibrin(ogen)-binding proteins and beta amyloid that may have relevance to Alzheimer's disease.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Project (R01)
Project #
5R01AG011525-05
Application #
2442269
Study Section
Special Emphasis Panel (ZRG1-NLS-3 (01))
Project Start
1992-09-30
Project End
1999-06-30
Budget Start
1997-08-01
Budget End
1998-06-30
Support Year
5
Fiscal Year
1997
Total Cost
Indirect Cost
Name
Rutgers University
Department
Type
Schools of Medicine
DUNS #
038633251
City
New Brunswick
State
NJ
Country
United States
Zip Code
08901
Qasim, M A; Lu, Wuyuan; Lu, Stephen M et al. (2003) Testing of the additivity-based protein sequence to reactivity algorithm. Biochemistry 42:6460-6
Khurana, S; Sanli, G; Powers, D B et al. (2000) Molecular modeling of substrate binding in wild-type and mutant Corynebacteria 2,5-diketo-D-gluconate reductases. Proteins 39:68-75
Qasim, M A; Lu, S M; Ding, J et al. (1999) Thermodynamic criterion for the conformation of P1 residues of substrates and of inhibitors in complexes with serine proteinases. Biochemistry 38:7142-50
Khurana, S; Powers, D B; Anderson, S et al. (1998) Crystal structure of 2,5-diketo-D-gluconic acid reductase A complexed with NADPH at 2.1-A resolution. Proc Natl Acad Sci U S A 95:6768-73
Kulikowski, C A; Zimmerman, D; Montelione, G et al. (1998) Structural-functional bioinformatics: knowledge-based NMR interpretation. Medinfo 9 Pt 1:365-6
Lu, W; Apostol, I; Qasim, M A et al. (1997) Binding of amino acid side-chains to S1 cavities of serine proteinases. J Mol Biol 266:441-61
Ma, L C; Anderson, S (1997) Correlation between disulfide reduction and conformational unfolding in bovine pancreatic trypsin inhibitor. Biochemistry 36:3728-36
Kim, S; Baum, J; Anderson, S (1997) Production of correctly folded recombinant [13C, 15N]-enriched guinea pig [Val90]-alpha-lactalbumin. Protein Eng 10:455-62
Castro, M J; Anderson, S (1996) Alanine point-mutations in the reactive region of bovine pancreatic trypsin inhibitor: effects on the kinetics and thermodynamics of binding to beta-trypsin and alpha-chymotrypsin. Biochemistry 35:11435-46
Abul Qasim, M; Ranjbar, M R; Wynn, R et al. (1995) Ionizable P1 residues in serine proteinase inhibitors undergo large pK shifts on complex formation. J Biol Chem 270:27419-22

Showing the most recent 10 out of 12 publications